Journal of Internal Medicine Concepts & Practice >
Follistatin like protein 1 mitigates oxidized low-density lipoprotein-stimulated phenotypic transformation of mouse vascular smooth muscle cell
Received date: 2021-01-06
Online published: 2022-07-26
Objective To investigate the effect of follistatin like protein 1(FSTL1) on oxidized low-density lipoprotein (Ox-LDL)-stimulated the phenotypic transformation of mouse vascular smooth muscle cell (VSMC). Methods Firstly, under Ox-LDL-stimulating, the expression of FSTL1 in VSMC was detected. Secondly, Western blotting was used to detect the signature proteins, α-smooth muscle actin(α-SMA) and osteopontin(OPN). Finally, the proliferation of VSMC was verified by proliferation experiments under the influence of Ox-LDL and FSTL1. Results Comparing to the normal group, the expression of FSTL1 was lower in the abnormal vessel regions, which was filled with Ox-LDL（0.223±0.010 vs. 0.097±0.019, P<0.01）. VSMC was stimulated by Ox-LDL at 0, 12.5, 25 and 50 mg/L for 24 h respectively and the expression level of FSTL1 detected by Western blotting was 1.330±0.055, 0.905±0.027, 0.753±0.037 and 0.243±0.016 accordingly. It showed that the lowest expression level of FSTL1 was observed when Ox-LDL concentration increased to 50 mg/L (F=260.600, P<0.000 1). The expression of FSTL1 was 1.383±0.033, 0.782±0.047, 0.381±0.022 and 0.230±0.017 after 50 mg/L Ox-LDL stimulating VSMC for 0, 6, 12 and 24 h respectively, in which the expression of FSTL1 was the lowest when Ox-LDL induced 24 h(F=151.000, P<0.000 1). In addition, Ox-LDL stimulation reduced the expression of α-SMA(1.303±0.030 vs. 0.493±0.069, P<0.01) and SIRT1(0.993±0.044 vs. 0.613±0.030, P<0.01), while increasing the expression of OPN(1.001±0.031 vs. 2.698±0.001, P<0.01). However, the expression of OPN, α-SMA and SIRT1 showed opposite trend when VSMC was stimulated with both FSTL1 and Ox-LDL（OPN 2.698±0.002 vs. 1.590±0.001, P<0.05; α-SMA 0.493±0.062 vs. 0.653±0.015, P<0.05; SIRT1 0.613±0.030 vs. 1.231±0.011, P<0.05）. Compared with Ox-LDL+FSTL1+DMSO group, VSMC in Ox-LDL+FSTL1+SIRT1 inhibitor group showed reduced α-SMA(0.530±0.033 vs. 0.283±0.032, P<0.01) and SIRT1(1.056±0.020 vs. 0.207±0.021, P<0.01), and increased OPN(1.643±0.047 vs. 3.533±0.100, P<0.01). The proliferation of VSMC was enhanced by Ox-LDL stimulation（0.870±0.010 vs. 1.890±0.020, P<0.01）, while FSTL1 reduced this proliferation（1.890±0.021 vs. 1.200±0.023, P<0.05） via SIRT1（1.280±0.033 vs. 2.030±0.092, P<0.01）. Conclusions Ox-LDL reduced the expression of FSTL1. FSTL1 could mitigate Ox-LDL-stimulated proliferation via SIRT1 effectively.
XIAO Fan, ZHA Qing, LIU Ya, YANG Ling, YE Jiawen, LIU Yan . Follistatin like protein 1 mitigates oxidized low-density lipoprotein-stimulated phenotypic transformation of mouse vascular smooth muscle cell[J]. Journal of Internal Medicine Concepts & Practice, 2021 , 16(03) : 172 -177 . DOI: 10.16138/j.1673-6087.2021.03.007
| [1] | Silva MC, Magalhães TA, Meira ZM, et al. Myocardial fibrosis progression in duchenne and becker muscular dystrophy[J]. JAMA Cardiol, 2017, 2(2): 190-199. |
| [2] | Alshehry ZH, Mundra PA, Barlow CK, et al. Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in type 2 diabetes mellitus[J]. Circulation, 2016, 134(21): 1637-1650. |
| [3] | Hwang JS, Ham SA, Yoo T, et al. Sirtuin 1 mediates the actions of peroxisome proliferator-activated receptor δ on the oxidized low-density lipoprotein-triggered migration and proliferation of vascular smooth muscle cells[J]. Mol Pharmacol, 2016, 90(5): 522-529. |
| [4] | Boucherat O, Peterlini T, Bourgeois A, et al. Mitochondrial HSP90 accumulation promotes vascular remodeling in pulmonary arterial hypertensionn[J]. Am J Respir Crit Care Med, 2018, 198(1): 90-103. |
| [5] | Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management[J]. BMJ, 2018, 360: j5492. |
| [6] | Hu S, Liu H, Hu Z, et al. Follistatin-like 1: a dual regulator that promotes cardiomyocyte proliferation and fibrosis[J]. J Cell Physiol, 2020, 235(9): 5893-5902. |
| [7] | Ni X, Cao X, Wu Y, et al. FSTL1 suppresses tumor cell proliferation, invasion and survival in non-small cell lung cancer[J]. Oncol Rep, 2018, 39(1): 13-20. |
| [8] | Shi N, Mei X, Chen SY. Smooth muscle cells in vascular remodeling[J]. Arterioscler Thromb Vasc Biol, 2019, 39(12): e247-e252. |
| [9] | He D, Xu L, Wu Y, et al. Rac3, but not Rac1, promotes ox-LDL induced endothelial dysfunction by downregulating autophagy[J]. J Cell Physiol, 2020, 235(2): 1531-1542. |
| [10] | Grebe A, Hoss F, Latz E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis[J]. Circ Res, 2018, 122(12): 1722-1740. |
| [11] | Yuan T, Yang T, Chen H, et al. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis[J]. Redox Biol, 2019, 20: 247-260. |
| [12] | Chellan B, Rojas E, Zhang C, et al. Enzyme-modified non-oxidized LDL (ELDL) induces human coronary artery smooth muscle cell transformation to a migratory and osteoblast-like phenotype[J]. Sci Rep, 2018, 8(1): 11954. |
| [13] | Gliozzi M, Scicchitano M, Bosco F, et al. Modulation of nitric oxide synthases by oxidized LDLs: role in vascular inflammation and atherosclerosis development[J]. Int J Mol Sci, 2019, 20(13): 3294. |
| [14] | Zhang Y, Xu X, Yang Y, et al. Deficiency of follistatin-like protein 1 accelerates the growth of breast cancer cells at lung metastatic sites[J]. J Breast Cancer, 2018, 21(3): 267-276. |
| [15] | Liu Q, Yu S, Zhao W, et al. EGFR-TKIs resistance via EGFR-independent signaling pathways[J]. Mol Cancer, 2018, 17(1): 53. |
| [16] | Walsh K. Adipokines, myokines and cardiovascular disease[J]. Circ J, 2009, 73(1): 13-18. |
/
| 〈 |
|
〉 |
